Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) and Compass Therapeutics (NASDAQ:CMPX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Profitability
This table compares Evaxion Biotech A/S and Compass Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evaxion Biotech A/S | N/A | -451.63% | -149.27% |
| Compass Therapeutics | N/A | -26.07% | -24.49% |
Risk and Volatility
Evaxion Biotech A/S has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evaxion Biotech A/S | 0 | 0 | 2 | 0 | 3.00 |
| Compass Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Evaxion Biotech A/S currently has a consensus price target of $11.00, suggesting a potential upside of 160.66%. Compass Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 504.03%. Given Compass Therapeutics’ higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Evaxion Biotech A/S.
Insider & Institutional Ownership
11.0% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by company insiders. Comparatively, 30.0% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Evaxion Biotech A/S and Compass Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evaxion Biotech A/S | $70,000.00 | 314.69 | -$22.12 million | ($6.76) | -0.62 |
| Compass Therapeutics | N/A | N/A | -$42.49 million | ($0.34) | -4.38 |
Evaxion Biotech A/S has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Compass Therapeutics beats Evaxion Biotech A/S on 6 of the 10 factors compared between the two stocks.
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.
